<bill session="116" type="h" number="4553" updated="2020-12-19T13:12:06Z">
  <state datetime="2019-09-27">REFERRED</state>
  <status>
    <introduced datetime="2019-09-27"/>
  </status>
  <introduced datetime="2019-09-27"/>
  <titles>
    <title type="official" as="introduced">To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever.</title>
    <title type="display">Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act</title>
    <title type="short" as="introduced">Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act</title>
  </titles>
  <sponsor bioguide_id="B001296"/>
  <cosponsors>
    <cosponsor bioguide_id="F000449" joined="2019-09-27"/>
    <cosponsor bioguide_id="M001198" joined="2019-09-27"/>
    <cosponsor bioguide_id="S001213" joined="2019-10-31"/>
    <cosponsor bioguide_id="V000131" joined="2019-09-27"/>
  </cosponsors>
  <actions>
    <action datetime="2019-09-27">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-09-27" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-09-30">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Infectious and parasitic diseases"/>
  </subjects>
  <amendments/>
  <summary date="2019-09-27T04:00:00Z" status="Introduced in House">Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act

This bill expands the priority-review voucher program for tropical diseases to include Middle East respiratory syndrome, Nipah virus, and Rift Valley fever. A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.</summary>
  <committee-reports/>
</bill>
